Happened in AI

NewsMedicine

UK government accepts all 44 recommendations from commission on regulating AI in healthcare

The UK government accepted all 44 recommendations of the MHRA-convened National Commission on regulating AI in healthcare, including lifelong monitoring of AI devices, but the detailed implementation plan is not due until spring 2027.

Evidence: 4 sources · 2 official records · 2 independent reports · 3 open questions

By Happened in AI Editors

Published
Read
2 min

What happened

  • On 10 September, the National Commission into the Regulation of AI in Healthcare, set up by the MHRA, published its final report with 44 recommendations.
  • On 6 October, the UK government said it accepted all 44.
  • The central recommendation is that AI medical devices be regulated across their whole working life, with ongoing real-world monitoring, not a one-time approval.
  • The government says a full implementation plan and roadmap will follow by spring 2027, with draft guidance on managing changes to AI devices planned for December 2026.

Why it matters

The UK's device rules were built for products that stay the same after approval. Accepting the commission's plan commits the government to a different model for AI that updates often and can behave differently from one hospital to another.

What is confirmed and what is claimed

Confirmed

  • The commission's report with 44 recommendations was published on 10 September (commission report coverage by Browne Jacobson and Digital Health Insights).
  • The government accepted all 44 recommendations on 6 October (GOV.UK press release and published response; also reported by The Pharmaceutical Journal and HTN). 1234
  • An implementation plan is due by spring 2027 (government response; Pharmaceutical Journal). 3
  • The MHRA opened applications for the third phase of its AI Airlock regulatory sandbox, which will test post-market monitoring (GOV.UK; Royal College of Physicians statement). 12

Claimed, not independently verified

  • The government describes its plan as a world-leading, agile approach to regulating AI devices.
  • Commentary on the report highlights proposals such as regulating products by their medical function, staged authorization of new AI models, public access to safety and incident information, and recording AI product versions in patient records; we have not checked each against the full report.

Most medical device rules assume a product is tested, approved, and then sold largely unchanged. AI tools break that assumption: they can be retrained, updated by their makers, or perform differently when the patients or equipment change. The National Commission, convened by the Medicines and Healthcare products Regulatory Agency (MHRA) with clinicians, lawyers, technologists, and patients, was asked how the UK should respond.

Context

Its answer is regulation that is proportionate to risk and runs through a product's whole life, with more weight on monitoring after a tool goes into use and less reliance on a single approval decision. By accepting every recommendation, the government has set the direction, but acceptance is a commitment, not a change in the law. The concrete rules, guidance, and any legislation are still to come.

The MHRA has since published a wider 2030 strategy and is presenting its approach to US industry, including plans for a staff member based in Washington to work with the FDA. For how health AI rules differ across countries, see our policy and safety map, and for what regulatory approval does and does not show, our guide to reading AI medicine news.

What to watch

  • Draft guidance on managing changes to AI devices, planned for December 2026.
  • The implementation plan and roadmap due by spring 2027, and the MHRA consultation on classifying AI software.
  • Results from the AI Airlock sandbox's third phase on monitoring devices in real use.

What we don’t know yet

  • What new legislation will be needed and when it will be laid before Parliament; the MHRA has indicated a consultation on classifying software and AI devices in spring 2027.
  • How lifelong monitoring will be paid for and who will carry it out in NHS trusts.
  • How the UK approach will line up with the EU AI Act and the FDA's rules, which matter to companies selling in several markets.

Evidence and sources

  1. Primary announcement Government backs recommendations of NHS doctors-led AI Commission GOV.UK ·
  2. Regulatory record Government Response to the National Commission's Recommendations on the Regulation of AI in Healthcare GOV.UK ·
  3. Independent reporting Government accepts all 44 recommendations from regulation of AI in healthcare report The Pharmaceutical Journal
  4. Independent reporting Government accepts National Commission into the Regulation of AI in Healthcare 44 recommendations HTN ·